REPLY
20.12.2023 09:31:34 CET | Business Wire | Press release
Concept Reply, part of the Reply network of companies and specialised in IoT, is working with MULTIVAC, a leading manufacturer of processing and packaging solutions, to develop smart services for automated machine monitoring. This project is part of the Open Industry 4.0 Alliance initiative, in which industry-specific companies have joined forces to develop common standards for the transformation to the Industrial Internet of Things.
As a member of the Open Industry 4.0 Alliance, Concept Reply contributes its expertise to IoT projects and actively supports the setting of standards in the field of Industrial IoT. In this context, Concept Reply is successfully working for international founding member MULTIVAC on the "smart services" project. This cloud IoT project aims to digitally manage machines - both locally and remotely - to make processes more transparent and to increase the efficiency and productivity of systems.
The cloud IoT platform implemented for MULTIVAC acts as a central monitoring and management instance. The data is processed on the platform and made available to users as smart services in freely configurable dashboards. The use of a micro-front-end architecture on the Azure cloud and the application of modern web technologies form the basis for the future use of AI-based assistants, thus laying the foundation for new business models and a sustainable, resource-efficient smart factory. The combination of cloud & edge computing reduces latency from data acquisition to sensor technology and actuator control. The benefits for the user are real-time data processing, protection against cyber-attacks and direct machine-to-machine communication.
Further projects with MULTIVAC are already in the pipeline to expand industry standards through the intelligent digitalisation of production and to actively shape the future of Industry 4.0. Dr Marius Grathwohl, VP Digital Products and Transformation at MULTIVAC and Member of the Board of the Alliance, concluded: "The successful collaboration between Concept Reply and MULTIVAC is based on the commonality of an open mindset and a shared understanding of Industry 4.0. Both companies are members of the Open Industry 4.0 Alliance, and we already have a common understanding of the architecture".
Together with its members, the Open Industry 4.0 Alliance is developing multi-vendor Industry 4.0 solutions and services for automated production systems and warehouses. Use cases include automated onboarding, device provisioning, device management, digital nameplates, digital twins and automated device lifecycle management. The open technical ecosystems enable machines and applications from different vendors to be networked and data to be securely transported along the value chain.
Reply
Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
Concept Reply
Concept Reply is an IoT software developer specializing in the research, development and validation of innovative solutions and supports its customers in the automotive, manufacturing, smart infrastructure and other industries in all matters relating to the Internet of Things (IoT) and cloud computing. The goal is to offer end-to-end solutions along the entire value chain: from the definition of an IoT strategy, through testing and quality assurance, to the implementation of a concrete solution. www.concept.reply.com
MULTIVAC Group
Bundled expertise, innovative top technology and strong brands under one roof: The MULTIVAC Group offers complete solutions for the packaging and processing of food, medical and pharmaceutical products as well as industrial goods - and continues to set new standards in the market as a technology leader. For more than 60 years, the name has stood for stability and values, innovation and sustainability, quality and excellent service. Founded in 1961 in the Allgäu region of Germany, the MULTIVAC Group is now a global solutions provider that helps small and medium-sized companies as well as large corporations to organise their production processes efficiently and in a way that conserves resources. www.multivac.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231220017040/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom